BRIEF—Cipla EU to invest an additional 3 million euros in Ethris

Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system.

This additional investment through a convertible loan will accelerate Cipla’s participation in the mRNA space.

Cipla had earlier invested 15 million euros in Ethris. 

This additional investment reaffirms Cipla’s confidence in Ethris’s proprietary mRNA platform and its potential for patients in emerging markets.

Together, Cipla and Ethris are working towards a long-term strategic partnership to fast-track innovative mRNA-based treatments.

During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.